Osgood, Tao

The Clinical KRAS(G12C) Inhibitor AMG 510 Drives Anti-Tumour Immunity

Canon, J., Rex, K., Saiki, A. Y., Mohr, C., Cooke, K., Bagal, D., Gaida, K., Holt, T., Knutson, C. G., Koppada, N., et al. (2019) · Nature

Protein Kinase Regulation and GTPase SignalingMelanoma and MAPK Pathways

Cited by 2,277

AMG 176, a Selective MCL1 Inhibitor, Is Effective in Hematologic Cancer Models Alone and in Combination with Established Therapies

Caenepeel, S., Brown, S. P., Belmontes, B., Moody, G., Keegan, K. S., Chui, D., Whittington, D. A., Huang, X., Poppe, L., Cheng, A. C., et al. (2018) · Cancer Discovery

Cell death mechanisms and regulationAcute Myeloid Leukemia Research

Cited by 432

Discovery of AMG 232, a Potent, Selective, and Orally Bioavailable MDM2–p53 Inhibitor in Clinical Development

Sun, D., Li, Z., Rew, Y., Gribble, M., Bartberger, M. D., Beck, H. P., Canon, J., Chen, A., Chen, X., Chow, D., et al. (2014) · Journal of Medicinal Chemistry

Cancer-related Molecular PathwaysHeterocyclic Compound Synthesis and Bioactivity

Cited by 290

The MDM2 inhibitor AMG 232 demonstrates robust antitumor efficacy and potentiates the activity of p53-inducing cytotoxic agents

Canon, J., Osgood, T., Olson, S. H., Saiki, A. Y., Robertson, R., Yu, D., Eksterowicz, J., Ye, Q., Jin, L., Chen, A., et al. (2015) · Molecular Cancer Therapeutics

Cancer-related Molecular PathwaysPI3K/AKT/mTOR signaling in cancer

Cited by 152

Rational Design and Binding Mode Duality of MDM2–p53 Inhibitors

Gonzalez-Lopez de Turiso, F., Sun, D., Rew, Y., Bartberger, M. D., Beck, H. P., Canon, J., Chen, A., Chow, D., Correll, T. L., Huang, X., et al. (2013) · Journal of Medicinal Chemistry

Cancer-related Molecular PathwaysHeterocyclic Compound Synthesis and Bioactivity

Cited by 82

MDM2 antagonists synergize broadly and robustly with compounds targeting fundamental oncogenic signaling pathways

Saiki, A. Y., Caenepeel, S., Yu, D., Lofgren, J. A., Osgood, T., Robertson, R., Canon, J., Su, C., Jones, A., Zhao, X., et al. (2014) · Oncotarget

Cancer-related Molecular PathwaysPI3K/AKT/mTOR signaling in cancer

Cited by 55